Imara announces results of interim analyses of tovinontrine (imr-687) phase 2b clinical trials in sickle cell disease and beta-thalassemia

Interim results in ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat population

ELVN Ratings Summary

ELVN Quant Ranking